Skip to main content
Clinical Trials/2024-516504-42-00
2024-516504-42-00
Recruiting
Phase 3

A randomised controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (pro.LISA)

Universitaetsklinikum Schleswig-Holstein AöR23 sites in 1 country698 target enrollmentJuly 31, 2024

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Universitaetsklinikum Schleswig-Holstein AöR
Enrollment
698
Locations
23
Primary Endpoint
Forced expiratory volume within the first second (... Forced expiratory volume within the first secoForced expiratory volume within the first second (FEV1) at 5 years of age (Global Lung Function Initiative z-score).
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The aim of the pro.LISA study is to clarify the question of whether prophylactic use of surfactant in premature infants with a gestational age of 25 weeks + 0 days to 30 weeks + 6 days leads to an improved forced expiratory volume within the first second (FEV1) at the age of 5 years. The aim of the pro.LISA study is to clarify the question of whether prophylactic use of surfactant in preterm infants with a gestational age of 25 weeks + 0 days to 30 weeks + 6 days leads to an improved forced expiratory volume within the first second (FEV1) at the age of 5 years.

Registry
euclinicaltrials.eu
Start Date
July 31, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Universitaetsklinikum Schleswig-Holstein AöR
Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. Wolfgang Göpel

Scientific

Universitaetsklinikum Schleswig-Holstein AöR

Eligibility Criteria

Inclusion Criteria

  • Preterm infants with a gestational age of 25+0 to 30+6 weeks of pregnancy
  • Age <= 60 minutes
  • Spontaneous breathing on CPAP
  • Pulse oximetrically measured saturation >=90% with a FiO2 <= 30%
  • Written informed consent of the legal guardian(s) (retrospectively if necessary)

Exclusion Criteria

  • Malformations or diseases with a probable lethal outcome
  • Hypersensitivity to surfactant, sodium hydrogen carbonate or sodium chloride

Outcomes

Primary Outcomes

Forced expiratory volume within the first second (... Forced expiratory volume within the first secoForced expiratory volume within the first second (FEV1) at 5 years of age (Global Lung Function Initiative z-score).

Forced expiratory volume within the first second (... Forced expiratory volume within the first secoForced expiratory volume within the first second (FEV1) at 5 years of age (Global Lung Function Initiative z-score).

Secondary Outcomes

  • At the age of 5 years: (1) FVC z-score, (2) FEV1/FVC z-score, (3) walking distance in the 3-minute walk test, (4) obstructive bronchitis treated with medication in the last 12 months, (5) cerebral palsy, defined as Gross Motor Function Classification System values > 1, (6) values in the Movement Assessment Battery for Children score, (7) intelligence quotient, determined with the WPPSI IV

Study Sites (23)

Loading locations...

Similar Trials